Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Delamanid: A new armor in combating drug‑resistant tuberculosis

    Alphienes Stanley Xavier1★, Mageshwaran Lakshmanan1★ Corresponding author

    1. 1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.

    CORRESPONDENCE

    Alphienes Stanley Xavier

    Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.

    Received: 20-01-2014; Revised: 08-03-2014; Accepted: 03-04-2014.

    Volume 5, Issue 3 · pp. 222–224 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.136121

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Intense search has been made in the discovery of newer anti‑TB drugs to tackle the issues such as drug resistance, HIV co‑infection and risk of drug‑drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR‑TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug‑drug interactions and better tolerability.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Xavier, A. S., & Lakshmanan, M. (2014). Delamanid: A new armor in combating drug‑resistant tuberculosis. Journal of Pharmacology and Pharmacotherapeutics, 5(3), 222–224. https://doi.org/10.4103/0976-500X.136121